GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cardiol Therapeutics Inc (TSX:CRDL) » Definitions » Median PS Value

Cardiol Therapeutics (TSX:CRDL) Median PS Value : C$0.00 (As of May. 02, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Cardiol Therapeutics Median PS Value?

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Cardiol Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was C$0. Cardiol Therapeutics's 10-Year median PS Ratio is . Therefore, the Median PS Value for today is C$0.00.

As of today (2024-05-02), Cardiol Therapeutics's share price is C$2.84. Cardiol Therapeutics's Median PS Value is C$0.00. Therefore, Cardiol Therapeutics's Price to Median PS Value for today is 0.00.

The historical rank and industry rank for Cardiol Therapeutics's Median PS Value or its related term are showing as below:

TSX:CRDL's Price-to-Median-PS-Value is not ranked *
in the Drug Manufacturers industry.
Industry Median: 0.85
* Ranked among companies with meaningful Price-to-Median-PS-Value only.

Cardiol Therapeutics Median PS Value Historical Data

The historical data trend for Cardiol Therapeutics's Median PS Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cardiol Therapeutics Median PS Value Chart

Cardiol Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Median PS Value
Get a 7-Day Free Trial - - - - -

Cardiol Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Median PS Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cardiol Therapeutics's Median PS Value

For the Drug Manufacturers - Specialty & Generic subindustry, Cardiol Therapeutics's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cardiol Therapeutics's Price-to-Median-PS-Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cardiol Therapeutics's Price-to-Median-PS-Value distribution charts can be found below:

* The bar in red indicates where Cardiol Therapeutics's Price-to-Median-PS-Value falls into.



Cardiol Therapeutics Median PS Value Calculation

Cardiol Therapeutics's Median PS Value for today is calculated as

Median PS Value=Revenue per Share (TTM)*10-Year Median PS Ratio
=0*
=0.00

10-Year Median PS Ratio is .
Cardiol Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cardiol Therapeutics  (TSX:CRDL) Median PS Value Explanation

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.

Cardiol Therapeutics's Price to Median PS Value for today is calculated as

Price to Median PS Value=Share Price/Median PS Value
=2.84/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cardiol Therapeutics Median PS Value Related Terms

Thank you for viewing the detailed overview of Cardiol Therapeutics's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Cardiol Therapeutics (TSX:CRDL) Business Description

Traded in Other Exchanges
Address
2265 Upper Middle Road East, Suite 602, Oakville, ON, CAN, L6H 0G5
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.

Cardiol Therapeutics (TSX:CRDL) Headlines

From GuruFocus

CEO Presenting on the Emerging Growth Conference on May 25 Register Now

By GuruFocusNews GuruFocusNews 05-24-2022

CEO Presenting on the Emerging Growth Conference on May 25 Register Now

By GuruFocusNews GuruFocusNews 07-03-2022

CEO Presenting on the Emerging Growth Conference on May 25 Register Now

By GuruFocusNews GuruFocusNews 06-03-2022

CEO Presenting on the Emerging Growth Conference on May 25 Register Now

By GuruFocusNews GuruFocusNews 06-13-2022

CEO Presenting on the Emerging Growth Conference on May 25 Register Now

By GuruFocusNews GuruFocusNews 06-23-2022

Heart Failure and CBD -- CFN Media

By Marketwired Marketwired 02-20-2019